[18F]AlF-NOTA-FAPI-04 PET/CT in Inflammation and Fibrosis in Renal Diseases

The goal of this observational study is to explore the feasibility of using 18F-labeled FAP molecular probe for PET/CT imaging (18F-FAPI PET/CT) to accurately evaluate inflammation and fibrosis in renal diseases. The main questions it aims to answer are:Can 18F-FAPI PET/CT accurately evaluate the inflammation and fibrosis of kidney disease?What is the value of 18F-FAPI PET/CT as a non-invasive assessment of inflammation and fibrosis in kidney disease? Participants will receive [18F]AlF-NOTA-FAPI-04 PET/CT and renal aspiration biopsy.

Inclusion Criteria:The pitients of nephritis or fibrosis diseaseExclusion Criteria:A. Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg; B. Renal biopsy cannot be performed for severe exclotting disease; C. Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor; D. Unable to cooperate with renal puncture biopsy due to language communication or other problems; E. Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception; F. Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes; G. alcohol allergy; H. Patients with significant decrease in urine volume due to disease; I: refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol; I: Other circumstances deemed inappropriate by the investigator for participation in the study.